Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

DYmista NAsal Spray in CHInese Patients (DYNAS-CHI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03599791
Recruitment Status : Completed
First Posted : July 26, 2018
Last Update Posted : February 22, 2022
Sponsor:
Information provided by (Responsible Party):
Viatris Inc. ( MEDA Pharma GmbH & Co. KG )

Brief Summary:
This study is a phase III clinical study to assess the efficacy and safety of Dymista® Nasal Spray in comparison to Azep® nasal spray and Flixonase® nasal spray in Chinese patients aged ≥ 12 years with moderate-to-severe allergic rhinitis/rhinoconjunctivitis.

Condition or disease Intervention/treatment Phase
Allergic Rhinitis Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Drug: Fluticasone Propionate 0.05 MG/ACTUAT Phase 3

Detailed Description:
This is a multicentre, randomized, active controlled prospective clinical trial in adult and adolescent patients with AR (seasonal and/or perennial), who have moderate-to-severe symptoms (rhinitis/ rhinoconjunctivitis), based on the Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 Guidelines. The study consists of a 3 to 7-day Lead-in Period during which patients must meet a minimum symptom severity score to be eligible for the Treatment Period. All patients will start the Lead-in Period straight after Screening Visit as soon as in/exclusion criteria are fulfilled. The Lead-in Period will be followed by a 14-day double-blind Treatment Period. At some time point during the study, patients will receive Placebo and Dymista® nasal spray or Azep® nasal spray or Flixonase® nasal spray, 1 spray per nostril twice daily according to randomization. On the first day of the Lead-in Period patients must meet study inclusion/exclusion criteria and have a sufficient AR symptom score to qualify for entry. Qualified patients will be requested to keep a Diary of nasal and ocular symptoms throughout the study period. Additionally, patients will be requested to complete the Adult Rhinoconjunctivitis Quality of Life Questionnaire (RQLQ) and EuroQoL 5D questionnaire (EQ-5D) on Day 1, Day 8 and Day 15. Both Questionnaires will be completed by adult patients only.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 900 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: Multicentre, randomized, double-blind, active controlled, parallel group study
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: Blinding device
Primary Purpose: Treatment
Official Title: Multicentre, Randomized, Double-blind, Parallel Group Phase III Study to Assess Efficacy and Safety of Dymista® Compared to Azep® and Flixonase® Nasal Sprays in the Treatment of Chinese Patients With Allergic Rhinitis/Rhinoconjunctivitis
Actual Study Start Date : June 29, 2018
Actual Primary Completion Date : September 24, 2019
Actual Study Completion Date : September 24, 2019

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Azelastine Hydrochl. + Fluticasone Prop.
Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT Nasal Spray, consists of a fixed-dose combination of azelastine hydrochloride and fluticasone propionate; 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
Drug: Azelastine Hydrochl./Fluticasone Prop. 0.137/0.05 MG/ACTUAT
Dymista Nasal spray suspension
Other Name: Dymista

Active Comparator: Azelastine hydrochloride
Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
Drug: Azelastine Hydrochloride 0.137 MG/ACTUAT
AZEP Nasal spray solution
Other Name: AZEP

Active Comparator: Fluticasone propionate
Drug: Fluticasone Propionate 0.05 MG/ACTUAT Nasal Spray, 1 spray per nostril twice daily for 14 days, with 3 to 7 days of lead-in period. At a certain point during the study, patients will receive Placebo.
Drug: Fluticasone Propionate 0.05 MG/ACTUAT
Fluticasone propionate nasal spray suspension
Other Name: Flixonase




Primary Outcome Measures :
  1. Combined 12-hour rTNSS (AM + PM) [ Time Frame: 14 days ]
    Total nasal symptom score (TNSSS) is a sum of 4 individual nasal symptom scores: nasal itching, runny nose, congestion and sneezing. Each nasal symptom will be assessed according to a 4-ponit scale (0 = no, 1 = mild, 2 = moderate, 3 = severe symptom); thus, each TNSS will be in the range from 0 (no symptoms at all) to 12 (all 4 symptoms are severe) and the combined 12-hour reflective TNSS (morning + evening) will be in the range of 0 to 24 accordingly



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   12 Years and older   (Child, Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

General Inclusion Criteria:

To be eligible for enrolment into this study, a patient must comply with all of the following criteria:

  1. Male or female patient 12 years of age or older.
  2. Provide written informed consent.
  3. Patients must have moderate-to-severe rhinitis or rhinoconjunctivitis, defined as rhinitis/rhinoconjunctivitis with one or more of the following being present:

    • Sleep disturbance.
    • Impairment of daily activities, leisure and/or sport.
    • Impairment of learning or work.
    • Troublesome symptoms.
  4. Patients must have moderate-to-severe rhinitis or rhinoconjunctivitis and monotherapy with either intranasal antihistamine or glucocorticoid is not considered sufficient at the discretion of the Investigator and/or designee.
  5. Conducting the Lead-in Period according to the protocol.
  6. Willing and able to comply with the study requirements.
  7. At least a 2-year history of AR (seasonal and/or perennial) during the same time of year as the scheduled study time.
  8. The presence of Immunoglobulin E (IgE)-mediated hypersensitivity to one or more aeroallergens present in current patient environment, confirmed by a positive response to an established standard diagnostic test at the site within the last year (before randomization).
  9. General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the Investigator or the sponsor's medical officer. When in doubt, the Investigator should confer with the sponsor's medical monitor or designee to determine eligibility for the study.
  10. Patient agrees to avoid prohibited medication and alcohol and use effective methods of contraception during the study.
  11. Negative pregnancy test in women with childbearing potential.

General Exclusion Criteria:

A patient is ineligible and must not enter the study if any of the following criteria is met:

Safety concerns:

  1. Presence of any hypersensitivity to drugs similar to azelastine hydrochloride, fluticasone propionate, or to any of the excipients.
  2. Women who are pregnant or nursing.
  3. Women of childbearing potential who are not abstinent or not practicing a medically acceptable method of contraception.
  4. Clinically significant arrhythmia (or unstable despite medical treatment) or symptomatic cardiac conditions.
  5. A known history of alcohol or drug abuse within the last 2 years.
  6. Diagnosis of human immunodeficiency virus (HIV) infection.
  7. Patients with a diagnosis of Glaucoma, cataract, or central serous chorioretinopathy (CSCR).

    Lack of suitability for the study:

  8. Nasal disease(s) likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa, clinically significant polyposis, or nasal structural abnormalities (e.g. nasal septum deviation).
  9. Nasal surgery or sinus surgery within the previous year.
  10. Chronic sinusitis - more than 3 episodes per year.
  11. Major malignancies including pheochromocytoma within the last 5 years. Exception will be considered where malignancies have been resolved as judged by Investigator.
  12. The use of any investigational drug within 30 days prior to Screening Visit. No other investigational products are permitted for use during the conduct of this study.
  13. Respiratory Tract Infections including within 14 days prior to Screening Visit.
  14. Asthma (with the exception of mild intermittent asthma). Patients with mild intermittent asthma who only require short-acting inhaled bronchodilators and who do not have nocturnal awakening as a result of asthma are eligible for enrolment.
  15. Other significant diseases of bronchus and lungs including chronic obstructive pulmonary disease (COPD), emphysema, bronchiectasis, tuberculosis, pneumonia.
  16. Any surgical or medical condition or physical or laboratory findings, which in the opinion of the Investigator or sponsor's medical monitor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug; that might significantly affect the patient's ability to complete this trial; or their safety in this trial.
  17. Clinically relevant abnormal physical findings during the Lead-in Period which, in the opinion of the Investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures.
  18. Current use or expected requirement of ritonavir or strong P4503A4 inhibitors including cobicistat-containing products.
  19. Specific immunotherapy within 6 months prior to Screening Visit. If the patient received immunotherapy a 6-month washout period is required following the last dose of immunotherapy.
  20. Use of certain medications or therapies (e.g. for Allergic Rhinitis) within a specified time period

    Administrative reasons:

  21. Planned travel outside of the aeroallergen area during the study period.
  22. Employees of the Sponsor, research centre or private practice and their family members.
  23. Start-of-treatment Visit (Day 1): have not fully completed Diary.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03599791


Locations
Show Show 33 study locations
Sponsors and Collaborators
MEDA Pharma GmbH & Co. KG
Investigators
Layout table for investigator information
Study Director: DucTung Nguyen, Dr. Meda Pharma GmbH & Co. KG (A Mylan Company)
Layout table for additonal information
Responsible Party: MEDA Pharma GmbH & Co. KG
ClinicalTrials.gov Identifier: NCT03599791    
Other Study ID Numbers: X-03065-3303
First Posted: July 26, 2018    Key Record Dates
Last Update Posted: February 22, 2022
Last Verified: February 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Viatris Inc. ( MEDA Pharma GmbH & Co. KG ):
Allergic Rhinitis
hayfever
rhinoconjunctivitis
azelastine
fluticasone
nasal spray
seasonal
perennial
TNSS
TOSS
Additional relevant MeSH terms:
Layout table for MeSH terms
Rhinitis
Rhinitis, Allergic
Respiratory Tract Infections
Infections
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases
Respiratory Hypersensitivity
Hypersensitivity, Immediate
Hypersensitivity
Immune System Diseases
Fluticasone
Xhance
Azelastine
Anti-Inflammatory Agents
Bronchodilator Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Anti-Asthmatic Agents
Respiratory System Agents
Dermatologic Agents
Anti-Allergic Agents
Lipoxygenase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Histamine H1 Antagonists, Non-Sedating
Histamine H1 Antagonists
Histamine Antagonists
Histamine Agents